Access is fundamental to our mission. It is not an initiative; it is our business model. Viatris works to be a model for sustainable access to medicine at scale and a reliable partner in addressing some of the world’s most enduring health challenges. We build access at scale with our extensive and diverse portfolio of medicines, meeting nearly every health need, a one-of-a-kind global supply chain designed to reach more people with health solutions when and where they experience need, and by leveraging our deep scientific expertise. The work Viatris is pursuing to scaling access and building more resilient healthcare systems is important to help make progress on the world’s collective goals to achieve health equity.
1The number of patients served is an estimate calculated using internal sales data (global volume of doses sold in 2023 in all markets as aligned with IQVIA standard units), divided by estimated per patient usage, which is based on treatment dose, treatment duration, and treatment adherence as estimated by Viatris Medical Affairs based on approved label indication and instructions for use, current international guideline recommendations, and common usage in clinical practice. Patients using multiple Viatris medicines may be counted as multiple patients. Certain adjustments were applied in consideration of completed and pending divestitures and to account for acceptable alternatives to the patient usage factors noted above, and rounded to the nearest hundred million. Estimates may be subject to reassessment.
